Logo image of PCLO.CA

PHARMACIELO LTD (PCLO.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:PCLO - CA71716K1012 - Common Stock

0.045 CAD
-0.01 (-18.18%)
Last: 8/5/2025, 7:00:00 PM
Fundamental Rating

0

Overall PCLO gets a fundamental rating of 0 out of 10. We evaluated PCLO against 30 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PCLO have multiple concerns. PCLO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PCLO has reported negative net income.
In the past year PCLO has reported a negative cash flow from operations.
PCLO had negative earnings in each of the past 5 years.
PCLO had a negative operating cash flow in each of the past 5 years.
PCLO.CA Yearly Net Income VS EBIT VS OCF VS FCFPCLO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

PCLO has a worse Return On Assets (-49.70%) than 79.41% of its industry peers.
Industry RankSector Rank
ROA -49.7%
ROE N/A
ROIC N/A
ROA(3y)-68.33%
ROA(5y)-74.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCLO.CA Yearly ROA, ROE, ROICPCLO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

The Gross Margin of PCLO (29.55%) is comparable to the rest of the industry.
The Profit Margin and Operating Margin are not available for PCLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCLO.CA Yearly Profit, Operating, Gross MarginsPCLO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

PCLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PCLO has been increased compared to 1 year ago.
Compared to 5 years ago, PCLO has more shares outstanding
Compared to 1 year ago, PCLO has a worse debt to assets ratio.
PCLO.CA Yearly Shares OutstandingPCLO.CA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M
PCLO.CA Yearly Total Debt VS Total AssetsPCLO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -14.68, we must say that PCLO is in the distress zone and has some risk of bankruptcy.
PCLO's Altman-Z score of -14.68 is on the low side compared to the rest of the industry. PCLO is outperformed by 88.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.68
ROIC/WACCN/A
WACC7.6%
PCLO.CA Yearly LT Debt VS Equity VS FCFPCLO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.11 indicates that PCLO may have some problems paying its short term obligations.
PCLO has a worse Current ratio (0.11) than 97.06% of its industry peers.
PCLO has a Quick Ratio of 0.11. This is a bad value and indicates that PCLO is not financially healthy enough and could expect problems in meeting its short term obligations.
PCLO's Quick ratio of 0.04 is on the low side compared to the rest of the industry. PCLO is outperformed by 97.06% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.04
PCLO.CA Yearly Current Assets VS Current LiabilitesPCLO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.04% over the past year.
Looking at the last year, PCLO shows a very strong growth in Revenue. The Revenue has grown by 125.72%.
PCLO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -16.56% yearly.
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.66%
Revenue 1Y (TTM)125.72%
Revenue growth 3Y-16.56%
Revenue growth 5YN/A
Sales Q2Q%361.89%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCLO.CA Yearly Revenue VS EstimatesPCLO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2M 4M 6M
PCLO.CA Yearly EPS VS EstimatesPCLO.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PCLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCLO.CA Price Earnings VS Forward Price EarningsPCLO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCLO.CA Per share dataPCLO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCLO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHARMACIELO LTD

TSX-V:PCLO (8/5/2025, 7:00:00 PM)

0.045

-0.01 (-18.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14
Earnings (Next)12-01 2025-12-01
Inst Owners0.18%
Inst Owner ChangeN/A
Ins Owners8.62%
Ins Owner ChangeN/A
Market Cap8.45M
Revenue(TTM)3.48M
Net Income(TTM)-9.14M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.43
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.02
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.7%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.55%
FCFM N/A
ROA(3y)-68.33%
ROA(5y)-74.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.08%
Cap/Sales 0.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.04
Altman-Z -14.68
F-Score4
WACC7.6%
ROIC/WACCN/A
Cap/Depr(3y)41.57%
Cap/Depr(5y)273.09%
Cap/Sales(3y)23.11%
Cap/Sales(5y)345.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.66%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)125.72%
Revenue growth 3Y-16.56%
Revenue growth 5YN/A
Sales Q2Q%361.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y56.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.85%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMACIELO LTD / PCLO.CA FAQ

What is the ChartMill fundamental rating of PHARMACIELO LTD (PCLO.CA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to PCLO.CA.


What is the valuation status of PHARMACIELO LTD (PCLO.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to PHARMACIELO LTD (PCLO.CA). This can be considered as Overvalued.


How profitable is PHARMACIELO LTD (PCLO.CA) stock?

PHARMACIELO LTD (PCLO.CA) has a profitability rating of 0 / 10.